38th week of 2020 patent applcation highlights part 28 |
Patent application number | Title | Published |
20200291326 | METHOD FOR PRODUCTION OF FATTY ACIDS - A process for production fatty acids comprising: adjusting pH of a saponifiable material to a value above pH 7 by adding alkaline material; saponifying all saponifiable material by passing alternate electrical current through the material, wherein the said step of saponification occurs in a saponification reactor; acidulating the saponified material by adding acid to pH value below 4; isolating obtained free fatty acids from aqueous layer. | 2020-09-17 |
20200291327 | METHODS FOR MAKING FREE FATTY ACIDS FROM SOAPS USING THERMAL HYDROLYSIS FOLLOWED BY ACIDIFICATION - Provided are methods, processes and systems for treating a soapstock. In alternative embodiments, provided are systems and methods for treating a soapstock to generate free fatty acids and/or fatty acid derivatives, e.g. fatty acid alkyl esters. In alternative embodiments, provided are systems and methods for realizing the full fatty acid yield of a soapstock by first converting substantially all of the saponifiable material in a soapstock to salts of fatty acids (soaps) and acidulating the soaps to generate free fatty acids and/or fatty acid derivatives, e.g. fatty acid alkyl esters, wherein the soapstock comprises soaps and saponifiable lipids, e.g. glycerides and/or phospholipids, and the generating of free fatty acids and/or fatty acid is achieved. | 2020-09-17 |
20200291328 | COMPOSITION FOR ALL NATURAL MULTIPURPOSE CLEANER - An all natural multipurpose cleaner composition includes: distilled water; lauryl glucoside (AG-60); aloe vera; vitamin E; ethyl alcohol (food grade); a preservative; and citric acid. Further embodiments of the composition include: tea tree oil; oregano; and a scent. The scent may include any of the following: lemon grass; cinnamon; sweet orange; rosemary; lemon and lime; pine; citronella; peppermint; eucalyptus; lavender; tea tree oil; and eucalyptus citriodora. | 2020-09-17 |
20200291329 | CLEANING PRODUCT - A cleaning product having a spray dispenser and a cleaning composition suitable for spraying and foaming, the composition is housed in the spray dispenser and the composition includes: i) from about 5 to about 15% by weight of the composition of a surfactant system; and ii) from about 0.1 to about 15% by weight of the composition of an specific ester. | 2020-09-17 |
20200291330 | Polypeptides and Compositions Comprising Such Polypeptides - The present invention relates to compositions such as cleaning compositions comprising enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes. | 2020-09-17 |
20200291331 | Methods for Cleansing Medical Devices - The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes. | 2020-09-17 |
20200291332 | CLEANING COMPOSITIONS COMPRISING ENZYMES - Cleaning compositions and methods of cleaning comprising endo-β-1,3-glucanase enzyme and surfactant. The weight ratio of surfactant to active endo-β-1,3-glucanase enzyme protein is at least about 1000:1. The compositions and methods are particularly for cleaning cotton fabrics. | 2020-09-17 |
20200291333 | METHOD FOR TREATING COTTON - A method of treating cotton comprising: (i) contacting cotton with an aqueous wash liquor comprising water and an endo-β-1,3-glucanase enzyme; (ii) optionally rinsing the cotton; and (iii) drying the cotton. The wash liquor may contain surfactant. The cotton may be contacted with the aqueous wash liquor with agitation. The method may be for removal of callose from cotton. The method may be for the manufacture of a cotton-containing fabric having improved whiteness maintenance, soil repellency, reduced malodour, anti-wrinkle benefits, and/or improved drying. | 2020-09-17 |
20200291334 | STORAGE-STABLE ENZYME PREPARATIONS, THEIR PRODUCTION AND USE - Described herein is a liquid enzyme preparation containing | 2020-09-17 |
20200291335 | LIQUID PRODUCT FOR STAINLESS-STEEL CORROSION REMEDIATION - A concentrate aqueous composition for removing Type I and Type III rouge from various stainless-steel items. The liquid composition comprises oxalic acid, a phosphonic acid, and various amines. The use of an amine has been found to provide synergistic results in removal of the noted types of corrosion from various stainless-steel items that include medical instruments, machines, equipment, pipes, tools, mixing and storage vessels, and the like. | 2020-09-17 |
20200291336 | NATURAL EDIBLE CLEANING COMPOSITION - A cleaning solution, composition, and portable cleaner are provided that is all natural, safe, non-toxic, edible, anti-bacterial, anti-viral, anti-microbial, deodorizing, and further includes a pleasant fragrance and taste. In addition, the cleaning composition can be free from sugar, alcohol, surfactants, and other harmful or harsh ingredients. In addition, the cleaning composition allows for quick cleaning of any type of object that may be placed in the mouth, such as pacifiers, toys, candy, eating utensils, musical instruments, and mouth-pieces, among others. | 2020-09-17 |
20200291337 | MICROBIOLOGICAL CULTURE PLATE - This disclosure relates to microbiological culture plates configured for providing hydrologic stability to an inoculant/sample placed upon solid media held within the plate. A culture plate includes a base section and a lid section shaped to fit upon and enclose the base section. The lid section includes an extension extending downward from an upper surface, and a cover attached to the lower end of the extension. The cover is configured so that when the lid section is placed upon the base section, the cover contacts the inoculant/sample placed upon the solid media in the base section. | 2020-09-17 |
20200291338 | GROWTH OF BACTERIAL HOST CELLS IN GAS PERMEABLE LOW-DENSITY POLYETHYLENE BAGS FOR PRODUCTION OF PLASMID DNA OR RECOMBINANT MOLECULES - The present disclosure pertains to methods of growing bacterial host cells in a low-density polyethylene (LDPE) bag to produce plasmid DNA or express recombinant protein. The LDPE bag is filled with media, an antibiotic, and host bacterial cells that have been transformed with plasmid DNA encoding a protein of interest. The LDPE bag is sealable to the external environment and incubated at a growth temperature until a desired concentration of bacteria is achieved. When plasmid DNA is desired, host cells are harvested and plasmid DNA is separated from host cell components. When recombinant protein is desired, expression is induced while host cells are in the LDPE bag, followed by the harvest and separation of the recombinant protein. The LDPE bags are sterile and conducive to bacterial growth equal to or greater than that afforded by conventional shake flasks under similar growth conditions. | 2020-09-17 |
20200291339 | CELL CULTURE CONTAINER HAVING MINUTE VOLUME - The invention relates to a cell culture container that inhibits adhesion of cells, a method for manufacturing the same and a method for producing cell aggregates using the same. The cell culture container has a coating film containing a copolymer having a recurring unit which contains a group represented by formula (a) and a recurring unit which contains a group represented by formula (b): | 2020-09-17 |
20200291340 | Lattice For Cell Culture - A lattice structure for culturing cells in a bioreactor is effective for culturing high density cells and maintaining cell type homogeneity. The lattice structure includes a plurality of channels forming a set of channels, each of the plurality of channels extending between a first channel pore surface and a second channel pore surface and each of the plurality of channels having a first channel pore and a second channel pore altogether forming a plurality of channel pores on each of the first channel pore surface and the second channel pore surface, wherein each of the channel pores has an area of between about 0.01 mm | 2020-09-17 |
20200291341 | PSEUDO SAMPLE CREATION METHOD AND APPARATUS, AND NUMERICAL MODEL CREATION SYSTEM AND METHOD - Human labor and time can be reduced, and a high-accuracy numerical model can be created. Provided is a pseudo sample creation method including mixing a pre-culture liquid medium that is not used to culture a sample, a post-culture liquid medium that is used to culture the sample, and an additive containing at least one of saccharides, an amino acid, a metabolite, and protein with one another to create a pseudo sample. In addition, provided is a numerical model creation system including: a spectrometer that acquires spectral data of a pseudo sample; a reference value measuring device that measures a reference value of the pseudo sample; and an analyzer that creates a numerical model representing a correlation between the spectral data and the reference value based on the spectral data and the reference values obtained from a plurality of pseudo samples. | 2020-09-17 |
20200291342 | POLYMERIC CELL CULTURE SURFACE HAVING HIGH CELL ADHESION - A polymeric substrate is contacted with a process gas and radio frequency electrical power is introduced in the process gas, forming a treated contact surface that has improved cell recovery compared to an untreated contact surface. The process gas optionally can be nitrogen gas, oxygen gas, or a gas that contains nitrogen atoms, oxygen atoms, or a combination of nitrogen and oxygen atoms. The process optionally improves cell recovery of a chicken embryo cell culture from the treated contact surface. | 2020-09-17 |
20200291343 | OPTOFLUIDIC PHOTOBIOREACTOR APPARATUS, METHOD, and APPLICATIONS - An optofluidic photoreactor including an optical waveguide having an input, characterized by an evanescent optical field confined along an outer surface of the optical waveguide produced by radiation propagating in the optical waveguide, means for inputting light to the input of the optical waveguide, and a photoactive material disposed substantially only within the evanescent field. A method for optically activating a photoactive material in an optofluidic photoreactor to convert carbon dioxide and water into other molecules that may be useful as a fuel or a chemical feedstock. | 2020-09-17 |
20200291344 | DEVICE AND METHOD FOR EXAMINING A MEDIUM - The invention relates to a device for examining a medium ( | 2020-09-17 |
20200291345 | DYNAMIC INCUBATOR SYSTEM AND METHOD - A dynamic incubator system and method for mammalian cells. The dynamic incubator system includes an incubator and a programming device communicatively coupled to the incubator. The programming device includes a memory, one or more processors, a display, and an input mechanism. The programming device is adapted to enable at least one preset temperature and gas concentration sequence to be one or more of designed for the interior of the incubator, saved to the memory of the programming device and/or selected for implementation within the interior of the incubator. The at least one temperature and gas concentration sequence includes programmed changes to the temperature and a CO | 2020-09-17 |
20200291346 | Customizable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System - Embodiments described herein generally relate to methods and systems for customizing protocols for use with a cell expansion system. Through a user interface, a user may create a custom task for loading, growing and/or harvesting cells. A custom task may comprise one or more steps, in which a user may add or omit steps, as desired. Data may be entered for settings associated with a custom task, in which embodiments provide for such data to be entered each time the custom task is performed. In another embodiment, the settings for a custom task may be configured, in which such settings may be stored and retrieved upon selection of the custom task. Customization and configuration of a custom task may occur using a diagram view of the cell expansion system, in which process settings are associated with graphical user interface elements. | 2020-09-17 |
20200291347 | METHODS FOR PERFORMING CELL CULTURE - The present invention relates to methods for performing cell culture by using a solid cell culture media form prepared by a 3D printing process. | 2020-09-17 |
20200291348 | DISSOLVABLE FOAM SCAFFOLDS FOR CELL CULTURE AND METHODS OF MAKING THE SAME - A dissolvable foam scaffold for cell culture is provided herein. The dissolvable foam scaffold includes an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof, and at least one first water-soluble polymer having surface activity. | 2020-09-17 |
20200291349 | METHODS FOR IMPROVEMENT OF SEMEN QUALITY - A method for improving quality of a mammalian semen sample includes providing an insoluble carrier carrying at least one ligand that binds to an indicator of impaired sperm membrane integrity and/or motility, or the insoluble carrier carrying at least one molecule capable of binding to the at least one ligand, and contacting the semen sample and the insoluble carrier to provide a bound sperm cell population and an unbound sperm cell population, The insoluble carrier may be a plurality of beads each carrying the at least one ligand or the at least one molecule. The indicator may be associated with one or both of impaired sperm acrosome and impaired sperm plasma membrane integrity. The ligand may be an antibody. The molecule may be one of streptavidin, protein A, and an anti-ligand antibody. Kits for performing the method are provided. | 2020-09-17 |
20200291350 | HEPATOCYTE CONSTRUCT AND METHOD FOR PRODUCING THE SAME - The presently disclosed subject matter is to provide a hepatocyte structure, particularly, a hepatocyte structure that mimics nonalcoholic steatohepatitis (NASH). | 2020-09-17 |
20200291352 | ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF - Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the like. | 2020-09-17 |
20200291353 | METHOD FOR PRODUCING CELL FLAPS - The present invention refers to an in vitro method for producing a flap of genetically modified cells on fibrin substrate and to the flap so obtained. | 2020-09-17 |
20200291354 | CELL SECRETED MINIBODIES AND USES THEREOF - The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer. | 2020-09-17 |
20200291355 | ENGINEERED ERYTHROID CELLS INCLUDING LOADABLE ANTIGEN-PRESENTING POLYPEPTIDES AND METHODS OF USE - The present disclosure provides customizable enucleated erythroid cells or enucleated cells that can be engineered to include, on their surface, a loadable exogenous antigen-presenting polypeptide, wherein the loadable exogenous antigen-presenting polypeptide comprises one or more amino acid substitutions. In some embodiments, the one or more amino acid substitutions stabilize the loadable exogenous antigen-presenting polypeptide on the cell surface. In some embodiments, the loadable exogenous antigen-presenting polypeptide is stabilized on the cell surface in the absence of a polypeptide bound to the loadable exogenous antigen-presenting polypeptide. In some embodiments, the loadable exogenous antigen-presenting polypeptide comprises an exogenous displaceable polypeptide bound to the loadable exogenous antigen-presenting polypeptide. In some embodiments, the loadable exogenous antigen-presenting polypeptide is stabilized on the cell surface upon release of the displaceable polypeptide. | 2020-09-17 |
20200291356 | CANINE BLOOD PLATELET PREPARATIONS - The present disclosure provides dry and liquid compositions that include canine platelets and/or canine platelet-derived substances in dried form or rehydrated form from a dried form of canine platelets and/or canine platelet-derived substances, as well as processes for preparing such compositions. The disclosure also provides processes for making the compositions and methods of using the compositions for therapeutic, prophylactic, diagnostic, and research purposes, and kits comprising the compositions. | 2020-09-17 |
20200291357 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS - The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed. | 2020-09-17 |
20200291358 | STEM CELL DERIVED FROM YOUNG PIG AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide stem cells having excellent proliferation ability and differentiation ability. The present invention relates to stem cells isolated from a neonatal pig, and a preparation method therefor. | 2020-09-17 |
20200291359 | ECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING SAME - The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index. | 2020-09-17 |
20200291360 | USE OF NOGGIN, AN ALK5 INHIBITOR AND A PROTEIN KINASE C ACTIVATOR, TO PRODUCE ENDOCRINE CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon. | 2020-09-17 |
20200291361 | COMPOSITION AND METHOD - The present disclosure relates to kidney organoids and methods of manufacturing the same. The organoids and methods may be used in a variety of applications such as disease modelling, drug screening, regenerative medicine and 5 scaling up production of kidney cells. | 2020-09-17 |
20200291362 | PROTEIN-INDUCED PLURIPOTENT CELL TECHNOLOGY AND USES THEREOF - A method of generating protein-induced pluripotent stem cells by delivering bacterially expressed reprogramming proteins into nuclei of starting somatic cells using the QQ-protein transduction technique, repeating several cell reprogramming cycles for creating reprogrammed protein-induced pluripotent stem cells, moving the reprogrammed cells into a feeder-free medium for expansion, and expanding and passaging the reprogrammed cells in a whole dish for generating homogeneous piPS cells. Also provided are the piPCS cells formed using this method and uses thereof. | 2020-09-17 |
20200291363 | TRANSCRIPTIONAL CONTROL IN PROKARYOTIC CELLS USING DNA-BINDING REPRESSORS - The present disclosure relates generally to methods and compositions for transferring a genetic circuit from one prokaryotic cell (“donor cell”) to another prokaryotic cell (“recipient cell” or “target cell” which are used interchangeably herein). More specifically, the present disclosure relates to prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins and the use of said donor cells in the efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding a RNA molecule or protein of interest. | 2020-09-17 |
20200291364 | Extracellular Redox Enzyme System to Alleviate Disease - Compositions comprising (i) lactate oxidase (LOX) and Catalase (CAT), preferably in a 1:1 molar ratio; or (ii) a fusion polypeptide comprising both LOX and CAT, e.g., LOXCAT, and methods of use thereof for reducing blood lactate levels, increasing blood pyruvate levels, and/or decreasing blood lactate/pyruvate ratio in a subject. | 2020-09-17 |
20200291365 | NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITY - The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates. | 2020-09-17 |
20200291366 | PROSS OPTIMIZED ENZYMES - The present invention provides enzymes that have been optimized by implementation of Protein Repair One Stop Shop (PROSS), an algorithm that generates protein design(s) for enhanced stability without changing either enzymatic properties or enzyme active site conformation of the respective enzyme. The protein design(s) generated by PROSS introduce mutations to the amino acid sequence of a wild-type protein, resulting in a mutated amino acid sequence that encodes a variant of the wild-type enzyme, i.e., “an enzyme variant”, which has an enhanced stability, core packing, surface polarity and backbone rigidity, a higher functional expression, and/or a combination thereof, compared to the stability core packing, surface polarity and backbone rigidity, functional expression and/or a combination thereof, of the wild-type enzyme. | 2020-09-17 |
20200291367 | LIPASES FOR USE IN WASHING AND CLEANING AGENTS - The invention is used in the field of enzyme technology. The invention relates to lipases and to the production thereof, the amino acid sequence of which has been modified in particular with regard to the use thereof in detergents and cleaning agents, all sufficiently similar lipases having a corresponding modification and nucleic acids coding for them. The invention further relates to methods and uses of said lipases and to agents containing them, in particular detergents and cleaning agents. | 2020-09-17 |
20200291368 | Improved CRISPR-Cpf1 Genome Editing Tool - The invention relates to a Cpf1-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cpf1 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting. | 2020-09-17 |
20200291369 | Improved CRISPR-Cas9 Genome Editing Tool - The invention relates to a Cas-based, preferably Cas9-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cas9 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting. | 2020-09-17 |
20200291370 | Mutant Cas Proteins - CRISPR/Cas Systems are provided where mutant Cas9 proteins or Cas9 proteins are provided that have improved binding to a target nucleic acid sequence having a functional PAM compared to wild type Cas9 or that bind to a target nucleic acid that lacks a functional PAM. | 2020-09-17 |
20200291371 | HEAT RESISTANT ISOAMYLASE - Provided are a novel isoamylase improved in optimum temperature, and more specifically, improved in heat resistance, and a process for producing the isoamylase. | 2020-09-17 |
20200291372 | Compositions Comprising Polypeptides Having Xylanase Activity and Polypeptides Having Arabinofuranosidase Activity - The present invention relates to compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity for use in, e.g., animal feed. The present invention further relates to polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2020-09-17 |
20200291373 | Treatment of a Condition Associated with Infection with an Oncogenic Bacterium - The present invention relates to the field of medicine, specifically to the field of treatment of a malignant condition associated with infection with a bacterium that aggravates and/or induces proliferation of the malignant conditions. | 2020-09-17 |
20200291374 | NOVEL METALLOPROTEASES - Aspects of the present compositions and methods relate to novel metalloproteases, polynucleotides encoding the novel metalloproteases, and compositions and methods for use thereof. | 2020-09-17 |
20200291375 | FUNGAL PROTEASE MIXTURES AND USES THEREOF - Fungal protease compositions, and more particularly, mixtures of | 2020-09-17 |
20200291376 | MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE - Provided are MTSP-1 polypeptides modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation. The modified MTSP-1 polypeptides that inhibit complement activation can be used for treatment of diseases and conditions in which complement activation plays a role. Such diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Exemplary of these disorders are ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal delayed graft function (DGF). | 2020-09-17 |
20200291377 | RAPID AND EFFICIENT DE-GLYCOSYLATION OF GLYCOPROTEINS - The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein, wherein, glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to cleave N-linked glycans in order to obtain de-glycosylated protein. A rapid tool for assessing the protein conformation by partial de-glycosylation is also presented wherein the partial de-glycosylated protein is analysed using capillary electrophoresis (CE-SDS). | 2020-09-17 |
20200291378 | GENETICALLY MODIFIED ISOPROPYLMALATE ISOMERASE ENZYME COMPLEXES AND PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREWITH - Genetically modified isopropylmalate isomerase enzyme complexes (e.g., LeuCD′ enzyme complexes), microbial organisms including genetically modified isopropylmalate isomerase enzyme complexes (e.g., LeuCD′), and processes for preparing C | 2020-09-17 |
20200291379 | ENZYME COMPOSITE INCLUDING HEME POLYMERASE AND HEME LIGASE, AND METHOD FOR PRODUCING HEMOZOIN USING SAME - The present invention relates to an enzym complex in which a heme polymerase and a heme ligase are linked to each other via the dockerin module of cellulas, and to a method for producing a hemozoin using the same. The enzyme complex according to the present invention can polymerize heme with higher efficiency than conventional enzymes, and thus can more efficiently produce hemozoin, a conductive biopolymer. | 2020-09-17 |
20200291380 | TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES - Described herein are compounds and methods for tethering proteins. For example, dimers of Protein X listed in Table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization and can be used to treat neurodegenerative diseases (such as, for example, Parkinson's Disease, ALS, Alzheimer's Disease, Huntington's Disease, Epilepsy, Frontotemporal Dementia, and/or DMD), cancer, autoimmune disease, and/or Celiac disease. | 2020-09-17 |
20200291381 | PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS - The invention in various aspects provides for magnetic enrichment and/or expansion of antigen-specific T cells, allowing for identification and characterization of antigen-specific T cells and their T cell receptors (TCRs) for therapeutic and/or diagnostic purposes, as well as providing for production of antigen-specific engineered T cells for therapy. Incubation of paramagnetic nano-aAPCs in the presence of a magnetic field, either during enrichment and/or expansion steps, activates T cells through magnetic clustering of paramagnetic particles on the T cell surface. | 2020-09-17 |
20200291382 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING - The disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof. | 2020-09-17 |
20200291383 | COMPOSITIONS AND METHODS FOR EDITING RNA - Compositions and methods for editing endogenous RNA molecules are provided. | 2020-09-17 |
20200291384 | HUMANIZED CELL LINE - A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza virus, isolation and growth much more effectively than corresponding conventional (unmodified) cells or in corresponding human virus receptor-overexpressing cells, and the propagated viruses may maintain higher genetic stability than in the corresponding cells. | 2020-09-17 |
20200291385 | STABILIZATION OF RNA - The present invention pertains to methods, uses, compositions and kits for treating RNA at conditions comprising a temperature of at least 70° C. and a pH of at least 8, preferably a pH of at least 9. It also pertains to methods, uses and compositions for stabilizing RNA at conditions comprising a temperature of at least 70° C. and a pH of at least 8, preferably a pH of at least 9. It based on the finding that RNA can be stabilized in the presence of ammonium sulfate. In particular, the present invention provides a method of processing RNA, comprising treating the RNA at conditions comprising a temperature of at least 70° C. and a pH of at least 8, preferably a pH of at least 9, in the presence of ammonium sulfate at a concentration of 10 mM or less. | 2020-09-17 |
20200291386 | METHOD FOR PRETREATMENT OF MICROBIAL CELLS - Methods and devices are provided for pretreatment of a sample containing microbial cells. In some embodiments, the pretreatment of the sample is performed via the initial selective lysis, within a sample pretreatment vessel, of non-microbial cells (such as blood cells) and the subsequent centrifugal separation of the sample to remove the resulting debris and concentrate the microbial cells. An immiscible and dense cushioning liquid may be included for collecting the microbial cells adjacent to the liquid interface formed by the cushioning liquid upon centrifugation of the pretreatment vessel. After removal of a substantial quantity of the supernatant, resuspension of the collected microbial cells, and re-establishment of the cushioning liquid interface, at least a portion of the remaining suspension may be removed without substantially removing the cushioning liquid. One or more intermediate wash cycles may be performed prior to extraction of the remaining suspension, which provides a “pretreated” sample. | 2020-09-17 |
20200291387 | PATHOGEN LYSIS AND NUCLEIC ACID EXTRACTION METHOD USING ZINC OXIDE NANOSTAR - The present invention relates to a method for lysing pathogen lysis and a method for extracting nucleic acid using zinc oxide nanostar, and the method for extracting nucleic acid using zinc oxide nanostar according to the present invention can extract nucleic acids by lysing cells of a pathogen without using a lysis buffer and can extract nucleic acid of high-purity and high-concentration by preventing nucleic acid degradation and fragmentation through various substances including salts contained in the lysis buffer at high concentration. In addition, the zinc oxide nanostar of the present invention (200 to 900 nm) has superior cell lysis capacity compared to the conventional zinc oxide nanoparticles (20 to 50 nm), thereby increasing the nucleic acid extraction efficiency and can extract at room temperature without a heating step to use as a field diagnostic method. | 2020-09-17 |
20200291388 | POLYNUCLEOTIDE CAPTURE MATERIALS, AND SYSTEMS USING SAME - Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations. | 2020-09-17 |
20200291389 | COMBINATORIAL PHOTO-CONTROLLED SPATIAL SEQUENCING AND LABELING - Methods of labeling or barcoding molecules within one or more portions of a plurality of cells are provided. Kits and systems for labeling or barcoding molecules within one or more portions of a plurality of cells are also provided. The methods, kits, and systems may utilize photo-controlled adapter sequences, nucleic acids tags, and/or linkers. | 2020-09-17 |
20200291390 | Recombinant Fusion Proteins and Libraries from Immune Cell Repertoires - Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof. | 2020-09-17 |
20200291391 | CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF - Disclosed are peptides and methods useful for identifying and producing capture agents based on epitopes of a target. In particular, disclosed are peptides comprising an epitope, where the peptide is cross-linked, where the epitope corresponds to an epitope of a target, wherein the peptide does not include the entire target, and where the cross-link is a disulfide, preferably a disulfide that naturally occurs in the target or between added or substitute cysteines. Also disclosed are methods of preparing such peptides and methods of using such peptides. In particular, in methods of identifying a target binding compound. | 2020-09-17 |
20200291392 | AUTOMATED SYSTEM FOR HTP GENOMIC ENGINEERING - The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest. | 2020-09-17 |
20200291393 | METHOD FOR MAKING A cDNA LIBRARY - This disclosure provides, among other things, a method for making a cDNA library. In some embodiments the method may comprise reverse transcribing mRNA to produce DNA:mRNA hybrids, treating the DNA:mRNA hybrids with RNAseH to produce mRNA fragments, and reverse transcribing the mRNA fragments. | 2020-09-17 |
20200291394 | CONJUGATION OF PEPTIDES TO SPHERICAL NUCLEIC ACIDS (SNAS) USING TRACELESS LINKERS - The present disclosure provides compositions and methods directed to combining spherical nucleic acid (SNA) components that are required for T-cell activation and proliferation. | 2020-09-17 |
20200291395 | NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS - The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, enginceled CRISPR systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates. | 2020-09-17 |
20200291396 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 2020-09-17 |
20200291397 | Influenza Virus Mutants and Uses Therefor - The disclosure relates to mutant recombinant influenza virus gene segment 7 with at least one mutation that modulates expression of M2 and M42 polypeptide. Also disclosed are recombinant influenza viruses comprising the mutant influenza virus gene segment 7, compositions comprising the mutant recombinant influenza virus gene segment 7, use of such mutant recombinant influenza virus gene segment 7 and mutant recombinant Influenza viruses. | 2020-09-17 |
20200291398 | GAPMERS AND METHODS OF USING THE SAME FOR THE TREATMENT OF MUSCULAR DYSTROPHY - The disclosure relates to compositions comprising a nucleotide sequence having two domains: a locked nucleic acid domain and a DNA gap domain, wherein nucleotide sequence binds to an endogenous DUX4 mRNA sequence disrupts DUX4 expression. | 2020-09-17 |
20200291399 | OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD - The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD. | 2020-09-17 |
20200291400 | MicroRNA Compounds and Methods for Modulating MIR-21 Activity - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 2020-09-17 |
20200291401 | METHODS OF RESCUING STOP CODONS VIA GENETIC REASSIGNMENT WITH ACE-TRNA - In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, and anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, and anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b)wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine. | 2020-09-17 |
20200291402 | METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS - The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c. 2991+1655 A>G CEP290 mRNA. | 2020-09-17 |
20200291403 | ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES - Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. | 2020-09-17 |
20200291404 | RNA HYDROGELS - Disclosed herein are RNA molecules with particular nucleotide sequences that, through Watson-Crick base pairing, enable the RNAs to form a hydrogel. | 2020-09-17 |
20200291405 | HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder. | 2020-09-17 |
20200291406 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. | 2020-09-17 |
20200291407 | TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF. | 2020-09-17 |
20200291408 | COMPOSITIONS AND METHODS FOR 3-HYDROXYPROPIONIC ACID PRODUCTION - The present application discloses genetically modified yeast cells comprising an active 3-HP fermentation pathway, and the use of these cells to produce 3-HP. | 2020-09-17 |
20200291409 | GAS VESICLE EXPRESSION SYSTEMS, GAS VESICLE CONSTRUCTS AND RELATED GENETIC CIRCUITS, VECTORS, MAMMALIAN CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS - Provided herein are genetically engineered gas vesicle expression systems (GVES) that are configured to express gas vesicles (GVs) in a mammalian cell, related gas vesicle polynucleotide constructs, gas vesicle reporting genetic circuits, vectors, genetically engineered mammalian cells, non-human mammalian hosts, compositions, methods and systems, which in several embodiments can be used together with contrast-enhanced imaging techniques to detect and report biological events in an imaging target site comprising a mammalian cell and/or organism. | 2020-09-17 |
20200291410 | Construction and Application of Engineering Bacteria Capable of Secreting and Expressing Diacetylchitobiose Deacetylase - The disclosure herein relates to construction and application of engineering bacteria capable of secreting and expressing diacetylchitobiose deacetylase, and belongs to the technical field of fermentation engineering. Firstly, recombinant | 2020-09-17 |
20200291411 | Inducible Production-Phase Promoters for Coordinated Heterologous Expression in Yeast - Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources. | 2020-09-17 |
20200291412 | Method for Increasing Lycopene Content in Tomato Fruit - The present disclosure provides a method for increasing lycopene content in a tomato fruit, including knocking out the gene LIE1 of SEQ ID No 1. The disclosure also provides a method for knocking out gene LIE1 in tomato. The method of the disclosure is effective for increasing the content of lycopene in tomato fruits. Finally, the disclosure provides a transgenic tomato plant with knockout of gene LIE1. | 2020-09-17 |
20200291413 | METHOD - The present invention provides a method for modulating the alkaloid content of a plant (e.g. a tobacco plant), the method comprising modifying said plant by modulating the activity or expression of at least one Nic1 ERF gene. The present invention also provides for the use of at least one Nic1 ERF gene for modulating the alkaloid content of a plant, as well as tobacco cells, plants, plant propagation materials, harvested leaves, processed tobaccos, or tobacco products obtainable in accordance with the invention. | 2020-09-17 |
20200291414 | Novel plants and methods for producing muconic acid - The present invention provides for a genetically modified plant or plant cell comprising a nucleic acid encoding one or more heterologous enzymes operatively linked a promoter, wherein one or more heterologous enzymes synthesizes muconic acid (MA). | 2020-09-17 |
20200291415 | SOYBEANS WITH REDUCED ANTINUTRITIONAL FACTOR CONTENT - Soybean plants with one or more non-transgenic human-induced mutations of the phytate transport genes, LPA-3 and LPA-19, and the agglutinin gene, LEC1, are disclosed. Soybean plants and seeds having reduced levels of phytate and/or lectin as a result of such non-transgenic human-induced mutations are provided. Meal prepared from soybean seeds provided herein is useful, for example, as a source of food or feed for poultry, human, swine, or fish, wherein the food or feed has reduced levels of antinutrient factors, including phytate and lectin. | 2020-09-17 |
20200291416 | INCREASING PLANT GROWTH AND YIELD BY USING A QUINONE OXIDOREDUCTASE - Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding quinone oxidoreductase proteins, polypeptides encompassing quinone oxidoreductase proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided. | 2020-09-17 |
20200291417 | MODULATION OF SEED VIGOR - The present invention provides a polynucleotide which enables the modulation of the seed vigour, and in particular enhances the seed vigour, and more particularly enables the modification of the speed of germination. A plant seed comprising the said polynucleotide is also provided. A method of producing the plant seed, method for improving the germination and vigour of plant seed, transgenic plant and the use of the polynucleotide of the invention for producing plants growing seeds with improved germination and vigour characteristics are also provided. The invention particularly concerns | 2020-09-17 |
20200291418 | MOLECULAR MARKERS LINKED TO DISEASE RESISTANCE IN SOYBEAN - The present invention relates to methods and compositions for identifying, selecting and/or producing a soybean plant or germplasm having a Rps1 resistance allele and resistance to | 2020-09-17 |
20200291419 | STRIPE RUST RESISTANCE GENE WTK1 (Yr15) AND USE THEREOF - Isolated DNA of the Wtk1 gene or a functional equivalent capable of conferring resistance to stripe rust, is provided, as well as artificial vectors comprising same, proteins encoded by same and nucleic acid molecules for detecting same. Transgenic plants, as well as cells, seeds, and tissue therefrom which express the Wtk1 gene or a functional equivalent thereof are also provided. | 2020-09-17 |
20200291420 | METHODS OF IDENTIFYING, SELECTING, AND PRODUCING SOUTHERN CORN RUST RESISTANT CROPS - The field is related to plant breeding and methods of identifying and selecting plants with resistance to southern corn rust. Provided are methods to identify novel genes that encode proteins providing plant resistance to southern corn rust and uses thereof. These disease resistant genes are useful in the production of resistant plants through breeding, transgenic modification, or genome editing. | 2020-09-17 |
20200291421 | Vitis Vinifera with Reduced MLO Expression and Increased Resistance to Powdery Mildew - Provided herein are | 2020-09-17 |
20200291422 | Cucumber Mosaic Virus Resistant Pepper Plants - The present disclosure provides | 2020-09-17 |
20200291423 | MAMMALIAN EXPRESSION SYSTEM - The present invention relates to an expression system for the heterologous expression of a nucleic acid sequence of interest in a mammalian cell, the system comprising: (i) a first genetic entity, comprising: a nucleic acid sequence encoding a functional Epstein Barr virus nuclear antigen 1 (EBNA-1), the nucleic acid sequence being operably linked to regulatory elements that allow for expression of the nucleic acid sequence encoding a functional EBNA-1; (ii) a second genetic entity, comprising: a nucleic acid sequence encoding a functional nucleoside diphosphate kinase A (NDPK-A), the nucleic acid sequence being operably linked to regulatory elements that allow for expression of the nucleic acid sequence encoding a functional NDPK-A; (iii) a third genetic entity, comprising: the nucleic acid sequence of interest being operably linked to regulatory elements that allow for expression of the nucleic acid sequence of interest; and (iv) a four genetic entity, comprising: the Epstein Barr virus OriP sequence or one or more subsequences thereof, wherein the one or more subsequences comprise at least the ‘Family of Repeats’ DNA-binding site for EBNA-1 and the ‘Dyad Symmetry’ DNA-binding site for EBNA-1. The present invention also relates to corresponding mammalian host cells and methods for expressing a nucleic acid sequence of interest by means of such expression system. | 2020-09-17 |
20200291424 | TARGETED DELETION OF CELLULAR DNA SEQUENCES - Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites. | 2020-09-17 |
20200291425 | METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME - Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR/Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided. | 2020-09-17 |
20200291426 | RECOMBINANT TRANSITION VECTOR FOR INCREASING FOREIGN PROTEIN EXPRESSION - Disclosed are a novel recombinant transition vector for increasing expression of a foreign protein in a native form without fusion partners, and a method for mass production of a foreign target protein using the same. The recombinant transition vector according to the present disclosure may allow a large amount of a foreign target protein with a high therapeutic and prophylactic value to be expressed in an insect cell. In particular, the vector may increase the expression of the foreign target protein in an own form thereof, not fused with other fusion partners. Therefore, the use of the recombinant transition vector may produce useful proteins such as antigens in insect cells at low cost and high efficiency. | 2020-09-17 |